|
1
|
Scher HI, Solo K, Valant J, Todd MB and
Mehra M: Prevalence of prostate cancer clinical states and
mortality in the United States: Estimates using a dynamic
progression model. PLoS One. 10:e01394402015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Angelis R, Sant M, Coleman MP,
Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H,
Ardanaz E, et al: Cancer survival in Europe 1999–2007 by country
and age: Results of EUROCARE-5-a population-based study. Lancet
Oncol. 15:23–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sweeney CJ, Chen YH, Carducci M, Liu G,
Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et
al: Chemohormonal therapy in metastatic hormone-sensitive prostate
cancer. N Engl J Med. 373:737–746. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herrera FG, Tawadros T and Berthold DR:
Bone metastases in prostate cancer: Pathophysiology, clinical
complications, actual treatment, and future directions. Bone
Cancer. Heymann D: 2nd. Elsevier; Amsterdam: pp. 657–663. 2015,
View Article : Google Scholar
|
|
6
|
Massagué J and Chen YG: Controlling
TGF-beta signaling. Genes Dev. 14:627–644. 2000.PubMed/NCBI
|
|
7
|
Akhurst RJ and Derynck R: TGF-beta
signaling in cancer-a double-edged sword. Trends Cell Biol.
11:S44–S51. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Derynck R, Muthusamy BP and Saeteurn KY:
Signaling pathway cooperation in TGF-β-induced
epithelial-mesenchymal transition. Curr Opin Cell Biol. 31:56–66.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Tian XJ, Zhang H, Teng Y, Li R,
Bai F, Elankumaran S and Xing J: TGF-β-induced
epithelial-to-mesenchymal transition proceeds through stepwise
activation of multiple feedback loops. Sci Signal. 7:ra912014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu W, Chen F, Cui X, Yang L, Chen J, Zhao
J, Huang D, Liu J, Yang L, Zeng J, et al: LncRNA NKILA suppresses
TGF-β-induced epithelial-mesenchymal transition by blocking NF-κB
signaling in breast cancer. Int J Cancer. 143:2213–2224. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gutschner T and Diederichs S: The
hallmarks of cancer: A long non-coding RNA point of view. RNA Biol.
9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qian H, Chen L, Huang J, Wang X, Ma S, Cui
F, Luo L, Ling L, Luo K and Zheng G: The lncRNA MIR4435-2HG
promotes lung cancer progression by activating β-catenin
signalling. J Mol Med (Berl). 96:753–764. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Edge SB and Compton CC: The American Joint
Committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hughes G: Youden's index and the weight of
evidence. Methods Inf Med. 54:198–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meulmeester E and Ten Dijke P: The dynamic
roles of TGF-β in cancer. J Pathol. 223:206–218. 2011. View Article : Google Scholar
|
|
17
|
Vo BT, Morton D Jr, Komaragiri S, Millena
AC, Leath C and Khan SA: TGF-β effects on prostate cancer cell
migration and invasion are mediated by PGE2 through activation of
PI3K/AKT/mTOR pathway. Endocrinology. 154:1768–1779. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fournier PG, Juárez P, Jiang G, Clines GA,
Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, et al:
The TGF-β signaling regulator PMEPA1 suppresses prostate cancer
metastases to bone. Cancer Cell. 27:809–821. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fan YH, Ji CX, Xu B, Fan HY, Cheng ZJ and
Zhu XG: Long noncoding RNA activated by TGF-β in human cancers: A
meta-analysis. Clin Chim Acta. 468:10–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li C, Wan L, Liu Z, Xu G, Wang S, Su Z,
Zhang Y, Zhang C, Liu X, Lei Z and Zhang HT: Long non-coding RNA
XIST promotes TGF-β-induced epithelial-mesenchymal transition by
regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer.
Cancer Lett. 418:185–195. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishita M, Hashimoto MK, Ogata S, Laurent
MN, Ueno N, Shibuya H and Cho KW: Interaction between Wnt and
TGF-beta signalling pathways during formation of Spemann's
organizer. Nature. 403:781–785. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tuxhorn JA, McAlhany SJ, Yang F, Dang TD
and Rowley DR: Inhibition of transforming growth factor-beta
activity decreases angiogenesis in a human prostate cancer-reactive
stroma xenograft model. Cancer Res. 62:6021–6025. 2002.PubMed/NCBI
|
|
23
|
Paller C, Pu H, Begemann DE, Wade CA,
Hensley PJ and Kyprianou N: TGF-β receptor I inhibitor enhances
response to enzalutamide in a pre-clinical model of advanced
prostate cancer. Prostate. 79:31–43. 2019. View Article : Google Scholar : PubMed/NCBI
|
